Wang Yang,Dong Rui.Progress in the treatment of Ewing’s sarcoma family tumor[J].Journal of Clinical Pediatric Surgery,2022,21(02):191-195.[doi:10.3760/cma.j.cn.101785-201909060-017]
尤文肉瘤家族治疗进展
- Title:
- Progress in the treatment of Ewing’s sarcoma family tumor
- 摘要:
- 尤文肉瘤家族（Ewing’s sarcoma family tumor，ESFT）是儿童常见的恶性骨肿瘤，具有侵袭性、溶骨性和明显传播倾向。目前多学科综合治疗方法使患儿预后得到了显著改善。但即使积极治疗，仍有20%~40%的原发肿瘤患儿和近80%的转移肿瘤患儿难获显著疗效。随着生物靶向治疗的研究进展，一些晚期尤文肉瘤（Ewing sarcoma，ES）患儿也能获得治愈的希望。各类靶点之间相互联系，靶向药物的组合可以起到显著的协同作用。尽管这些特定治疗剂本身不可能完全消除ESFT，但这些药物与传统疗法相结合，通过干扰肿瘤细胞存活所必需的不同途径，进而协同杀伤肿瘤细胞并减少耐药，是未来治疗的大方向。
- Abstract:
- As a common malignant bone tumor in children, Ewing’s sarcoma family tumor (ESFT) has the clinical characteristics of aggressiveness, osteolysis and obvious metastatic tendency.A multidisciplinary therapeutic approach has markedly improved the prognosis of ESFT patients.Despite aggressive interventions, still 20-40% of patients have local diseases and nearly 80% are metastatic without any significant efficacy.With a rapid development of biotargeted therapies, some patients with advanced ES may see the promise of a cure.Some kinds of targets are interrelated and combining targeted drugs offers significant synergies.Although these specific therapeutic agents alone are unlikely to completely eliminate ESFT, combining these drugs and traditional therapies, by interfering with different pathways necessary for the survival of tumor cells, synergistically killing tumor cells and reducing drug resistance, is a major therapeutic direction in the future.
参考文献/References:
[1] Delattre O,Zucman J,Melot T,et al.The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts[J].N Engl J Med,1994,331(5):294- 299.DOI:10.1056/NEJM199408043310503.
[2] Bernstein M,Kovar H,Paulussen M,et al.Ewing’s sarcoma family of tumors:current management[J].Oncologist,2006,11(5):503- 519.DOI:10.1634/theoncologist.11- 5- 503.
[3] Esiashvili N,Goodman M,Marcus RB.Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades:Surveillance Epidemiology and End Results data[J].J Pediatr Hematol Oncol,2008,30(6):425- 430.DOI:10.1097/MPH.0b013e31816e22f3.
[4] Balamuth NJ,Womer RB.Ewing’s sarcoma[J].Lancet Oncol,2010,11(2):184- 192.DOI:10.1016/S1470- 2045(09)70286- 4.
[5] Jiang Y,Ludwig J,Janku F.Targeted therapies for advanced Ewing sarcoma family of tumors[J].Cancer Treat Rev,2015,41(5):391- 400.DOI:10.1016/j.ctrv.2015.03.008.
[6] Chen S,Kemal D,Sung YS,et al.Ewing sarcoma with ERG gene rearrangements:A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH[J].Genes Chromosomes Cancer,2016,55(4):340- 349.DOI:10.1002/gcc.22336.
[7] Shing DC,Mcmullan DJ,Roberts P,et al.FUS/ERG gene fusions in Ewing’s tumors[J].Cancer Res,2003,63(15):4568- 4576.
[8] Kilpatrick SE,Reith JD,Rubin B.Ewing sarcoma and the history of similar and possibly related small round cell tumors[J].Adv Anat Pathol,2018,25(5):314- 326.DOI:10.1097/pap.0000000000000203.
[9] Maheshwari AV,Cheng EY.Ewing sarcoma family of tumors[J].J Am Acad Orthop Surg,2010,18(2):94- 107.DOI:10.5435/00124635- 201002000- 00004.
[10] Thacker MM,Temple HT,Scully SP.Current treatment for Ewing’s sarcoma:expert review of anticancer therapy[J].Expert Rev Anticancer Ther,2005,5(2):319- 331.DOI:10.1586/14737140.5.2.319.
[11] Sluga M,Windhager R,Lang S,et al.The role of surgery and resection margins in the treatment of Ewing’s sarcoma[J].Clin Orthop Relat Res,2001,392(392):394- 399.DOI:10.1097/00003086- 200111000- 00051.
[12] Renard AJS,Veth RPH,Schreuder HWB,et al.Functional results and complications after ablative and limb-saving therapy in lower extremity sarcoma of bone[J].Eur J Cancer,1999,35(9):S267- S268.DOI:10.1016/s0959- 8049(99)81486- 5.
[13] Choi Y,Lim DH,Lee SH,et al.Role of radiotherapy in the multimodal treatment of ewing sarcoma family tumors[J].Cancer Res Treat,2015,47(4):904- 912.DOI:10.4143/crt.2014.158.
[14] Paulino AC.Late effects of radiotherapy for pediatric extremity sarcomas[J].Int J Radiat Oncol Biol Phys,2004,60(1):265- 274.DOI:10.1016/j.ijrobp.2004.02.001.
[15] Grier HE,Krailo MD,Tarbell NJ,et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone[J].N Engl J Med,2003,348(8):694- 701.DOI:10.1056/NEJMoa020890.
[16] Grünewald TGP,Cidre-Aranaz F,Surdez D,et al.Ewing sarcoma[J].Nat Rev Dis Primers,2018,4(1).DOI:10.1038/s41572- 018- 0003- x
[17] Krasin MJ,Davidoff AM,Rodriguez-Galindo C,et al.Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors:local outcome and prognostic factors[J].Cancer,2005,104(2):367- 373.DOI:10.1002/cncr.21160.
[18] Subbiah V,Langanedu-Cgerradi SE,Cuqlievan B,et al.Multimodality treatment of desmoplastic small round cell tumor:chemotherapy and complete cytoreductive surgery improve patient survival[J].Clin Cancer Res,2018,24(19):4865- 4873.DOI:10.1158/1078- 0432.ccr- 18- 0202.
[19] Mctiernan A,Driver D,Michelagnoli MP,et al.High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours[J].Ann Oncol,2006,17(8):1301- 1305.DOI:10.1093/annonc/mdl108.
[20] Whelan J,Le Deley MC,Dirksen U,et al.High-Dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma:results of Euro-E.W.I.N.G.99 and ewing-2008[J].J Clin Oncol,2018,36(31):3110- 3119.DOI:10.1200/jco.2018.78.2516.
[21] Rosenthal J,Pawlowska AB.High-dose chemotherapy and stem cell rescue for high-risk Ewing’s family of tumors[J].Expert Rev Anticancer Ther,2011,11(2):251- 262.DOI:10.1586/era.10.215.
[22] Gaspar N,Hawkins DS,Dirksen U,et al.Ewing sarcoma:current management and future approaches through collaboration[J].J Clin Oncol,2015,33(27):3036- 3046.DOI:10.1200/JCO.2014.59.5256.
[23] Vren A,Toretsky JA.Ewing’s sarcoma oncoprotein EWS-FLI1:the perfect target without a therapeutic agent[J].Future Oncol,2005,1(4):521- 528.DOI:10.2217/14796694.1.4.521.
[24] Magnaghi-Jaulin L,Masutani H,Robin P,et al.SRE elements are binding sites for the fusion protein EWS-FLI-1[J].Nucleic Acids Res,1996,24(6):1052- 1058.DOI:10.1093/nar/24.6.1052..
[25] Siligan C,Ban J,Bachmaier R,et al.EWS-FLI1 target genes recovered from Ewing’s sarcoma chromatin[J].Oncogene,2005,24(15):2512- 2524.DOI:10.1038/sj.onc.1208455.
[26] Kelleher FC,Thomas DM.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours[J].Clin Sarcoma Res,2012,2(1):6.DOI:10.1186/2045- 3329- 2- 6.
[27] Shimizu R,Tanaka M,Tsutsumi S,et al.EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma[J].Cancer Sci,2018,109(9):2907- 2918.DOI:10.1111/cas.13710.
[28] Selvanathan SP,Graham GT,Grego AR,et al.EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex[J].Nucleic Acids Res,2019,47(18):9619- 9636.DOI:10.1093/nar/gkz699.
[29] Gorthi A,Romero JC,Loranc E,et al.EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma[J].Nature,2018,555(7796):387- 391.DOI:10.1038/nature25748.
[30] Anderson PM,Bielack SS,Gorlick RG,et al.A phase II study of clinical activity of SCH 717454(robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma[J].Pediatr Blood Cancer,2016,63(10):1761- 1770.DOI:10.1002/pbc.26087.
[31] Sun H,Lin DC,Cao Q,et al.CRM1 inhibition promotes cytotoxicity in ewing sarcoma cells by repressing EWS-FLI1-Dependent IGF-1 signaling[J].Cancer Res,2016,76(9):2687- 2697.DOI:10.1158/0008- 5472.can- 15- 1572.
[32] Heitzeneder S,Sotillo E,Shern JF,et al.Pregnancy-Associated plasma Protein-A (PAPP-A) in ewing sarcoma:role in tumor growth and immune evasion[J].J Natl Cancer Inst,2019,111(9):970- 982.DOI:10.1093/jnci/djy209.
[33] Henrich IC,Young R,Quick L,et al.USP6 confers sensitivity to IFN-Mediated apoptosis through modulation of TRAIL signaling in ewing sarcoma[J].Mol Cancer Res,2018,16(12):1834- 1843.DOI:10.1158/1541- 7786.mcr- 18- 0289.
[34] Yan S,Li Z,Thiele CJ.Inhibition of STAT3 with orally active JAK inhibitor,AZD1480,decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo[J].Oncotarget,2013,4(3):433- 445.DOI:10.18632/oncotarget.930.
[35] Koppenhafer SL,Kelli LG,William WT,et al.mTORC1/2 and protein translation regulate levels of CHK1 and the sensitivity to CHK1 inhibitors in ewing sarcoma cells[J].Mol Cancer Ther,2018,17(12):2676- 2688.DOI:10.1158/1535- 7163.mct- 18- 0260.
[36] Slotkin EK,Patwardhan PP,Vasudeva SD,et al.MLN0128,an ATP-Competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity,as potential therapy for bone and soft-tissue sarcoma[J].Mol Cancer Ther,2015,14(2):395- 406.DOI:10.1158/1535- 7163.mct- 14- 0711.
[37] Thoenen E,Curl A,Iwakuma T.TP53 in bone and soft tissue sarcomas[J].Pharmacol Ther,2019,202:149- 164.DOI:10.1016/j.pharmthera.2019.06.010.
[38] Huang X,Wu F,Zhang Z,et al.Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors:a meta-analysis[J].Biosci Rep,2019,39(3):1- 9.DOI:10.1042/bsr20181832.
[39] Sand LG,Szuhai K,Hogendoorn PC.Sequencing overview of Ewing sarcoma:a journey across genomic,epigenomic and transcriptomic landscapes[J].Int J Mol Sci,2015,16(7):16176- 16215.DOI:10.3390/ijms160716176.
[40] Thoenen E,Curl A,Iwakuma T.TP53 in bone and soft tissue sarcomas[J].Pharmacol Ther,2019,202:149- 164.DOI:10.1016/j.pharmthera.2019.06.010.
[41] Stolte B,Iniguez AB,Dharia NV,et al.Genome-scale CRI SPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma[J].J Exp Med,2018,215(8):2137- 2155.DOI:10.1084/jem.20171066.
[42] Guerzoni C,Fiori V,Terracciano M,et al.CD99 triggering in ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin[J].Clin Cancer Res,2015,21(1):146- 156.DOI:10.1158/1078- 0432.CCR- 14- 0492.
[43] Fisher JP,Flutter B,Wesemann F,et al.Effective combination treatment of GD2-expressing neuroblastoma and Ewing’s sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+γδT cells[J].Oncoimmunology,2015,5(1):e1025194.DOI:10.1080/2162402x.2015.1025194.
[44] Grisendi G,Spano C,D’souza N,et al.Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas[J].Stem Cells,2015,33(3):859- 869.DOI:10.1002/stem.1903.
[45] Kailayangiri S,Altvater B,Spurny C,et al.Targeting ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G[J].Oncoimmunology,2017,6(1):e1250050.DOI:10.1080/2162402x.2016.1250050.
相似文献/References:
[1]陈芝雪,董瑞.肝母细胞瘤多学科治疗方案的研究进展[J].临床小儿外科杂志,2020,19(05):398.[doi:10.3969/j.issn.1671-6353.2020.05.005]
Chen Zhixue,Dong Rui.Advances in the treatment of hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(02):398.[doi:10.3969/j.issn.1671-6353.2020.05.005]
[2]洪博,董瑞.肾母细胞瘤治疗研究进展[J].临床小儿外科杂志,2021,20(06):569.[doi:10.12260/lcxewkzz.2021.06.012]
Hong Bo,Dong Rui.Recent advances in the treatment of Wilms tumor[J].Journal of Clinical Pediatric Surgery,2021,20(02):569.[doi:10.12260/lcxewkzz.2021.06.012]
备注/Memo
收稿日期:2020-09-23。
通讯作者:董瑞,Email:rdong@fudan.edu.cn